CliffBio
small molecule

HYDROXYZINE PAMOATE

HYDROXYZINE PAMOATE

Loss of exclusivity—loss of exclusivity
CompanyPar →See this company's full patent-cliff portfolio

Drug detail

Brand nameHYDROXYZINE PAMOATE
Active ingredientHYDROXYZINE PAMOATE
StrengthEQ 25MG HYDROCHLORIDE
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalMarch 1986
Marketing statusDISCN

More from Par

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

HYDROXYZINE PAMOATE patent cliff — loss of exclusivity — | CliffBio